Non Small Cell Lung CarcinomaPhase 3ZPACTNCT00086268
Non-small Cell Lung Cancer Study US75 (Z-PACT)
A Phase 3 study testing zoledronic acid, Taxotere and Carboplatin in people with Non Small Cell Lung Carcinoma, run by Novartis Pharmaceuticals at 80 sites in United States.
Trial summary
This study will evaluate the effects of an investigational drug in combination with chemotherapy in patients with stage IIIB/IV non-small cell lung cancer. This study will measure the effects of this combination on progression of lung cancer, cancer response to treatments, and development of cancer-related bone… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non Small Cell Lung Carcinoma
- What is being tested?
- zoledronic acid, Taxotere and Carboplatin
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 250 participants
- Where
- 80 sitesUnited States
- Study dates
- Apr 2004to Oct 2007
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or Female patients at least of 18 years old
- Patients with diagnosed non-small cell lung cancer that cannot be treated by surgery
- Women must not be pregnant or attempting to become pregnant
- Able and willing to sign informed consent
Who cannot join
- Patients with cancer that has spread to the bone
- Patients with cancer that has spread to the brain who are receiving treatment
- Patients with kidney disease
- Patients treated with other investigational drugs
Trial locations and contacts
80 sites in 1 country.
80 sites in 1 country
United States80 sites
New Mexico Oncology Hematology Consultants, Ltd.
Albuquerque, New Mexico, 87109
Peachtree Hematology & Oncology
Atlanta, Georgia, 30309
Emory University
Atlanta, Georgia, 30322
Barberton Citizens Hospital-Cancer Center
Barberton, Ohio, 44203
Hematology/Oncology Clinic
Baton Rouge, Louisiana, 70808
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, 70809
Engracio Cortes, MD
Bayside, New York, 11361
Odyssey Research
Belle Haven, Virginia, 23306
Oncology Care Associates
Bethesda, Maryland, 20817
Lynn Regional Cancer Center
Boca Raton, Florida, 33428
Charleston Hematology Oncology
Charleston, South Carolina, 29403
Charleston Cancer Center
Charleston, South Carolina, 29406
Presbyterian Hospital
Charlotte, North Carolina, 28204
St. Louis Cancer Care
Chesterfield, Missouri, 63017
Advocate Illinois Masonic Medical Center Creticos Cancer Center
Chicago, Illinois, 60657
Cancer Center of Colorado Springs
Colorado Springs, Colorado, 80907
Liberty Hematology-Oncology
Columbia, South Carolina, 29203
Cancer Specialists of South Texas
Corpus Christi, Texas, 78412
Dayton Clinical Oncology Program
Dayton, Ohio, 45429
Karmanos Cancer Institute
Detroit, Michigan, 48201
East Orange VA Medical System
East Orange, New Jersey, 07018
NorthBay Cancer Center
Fairfield, California, 94533
San Juan Regional Cancer Ctr.
Farmington, New Mexico, 87401
The Jones Clinic
Germantown, Tennessee, 38138
Arena Oncology Assoc.
Great Neck, New York, 11021
Southern Oncology Research
Grifton, North Carolina, 28530
Straub Clinic & Hospital
Honolulu, Hawaii, 96813
Kaiser Foundation Hospital
Honolulu, Hawaii, 96819
Clinical Research Consultants
Hoover, Alabama, 35216
Howell Office Plaza
Howell Township, New Jersey, 07731
New Hope Cancer Centers
Hudson, Florida, 34667
Central Indiana Cancer Centers
Indianapolis, Indiana, 46219
NEA Clinic
Jonesboro, Arkansas, 72401
Kalamazoo Hematology & Oncology
Kalamazoo, Michigan, 49048
Oceola Cancer Center
Kissimmee, Florida, 34741
Knoxville Cancer Center
Knoxville, Tennessee, 27909
Oncology Institute of Greater Lafayette
Lafayette, Indiana, 47904
Southern Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
Nevada Cancer Center
Las Vegas, Nevada, 89109
Kansas City Cancer Ctr. South
Lenexa, Kansas, 66214
Southeast Nebraska Cancer Center
Lincoln, Nebraska, 68510
UCLA
Los Angeles, California, 91401
Atlantic Hem Onc Associates, LLC
Manasquan, New Jersey, 08736
Hematology Oncology Associates
Medford, Oregon, 97504
VA Medical Center
Miami, Florida, 33125
Innovative Medical Research of South Florida, Inc.
Miami Shores, Florida, 33138
Clinical Trials and Research Associates, Inc.
Montebello, California, 90640
West Virginia University
Morgantown, West Virginia, 26506
Hematology/Oncology Assoc. of South Jersey
Mount Holly, New Jersey, 08060
Community Hospital, Cancer Research Dept.
Munster, Indiana, 46321
NCH Healthcare System Oncology Research
Naples, Florida, 34102
Cancer Specialists of Oklahoma
Oklahoma City, Oklahoma, 73112
Med. Oncology Care Associates
Orange, California, 92868
Metcare Oncology
Ormond Beach, Florida, 32174
Hematology-Oncology Associates
Pensacola, Florida, 32501
Berkshire Hematology Oncology PC
Pittsfield, Massachusetts, 01201
James P. Wilmot Cancer Center
Rochester, New York, 16642
OSF Center for Cancer Care
Rockford, Illinois, 61108
Park Nicollett Institute
Saint Louis Park, Minnesota, 55416
Cancer Center of Santa Barbara
Santa Barbara, California, 93105
New Mexico Cancer Care Associates
Santa Fe, New Mexico, 87505
Maine Center for Cancer Medicine
Scarborough, Maine, 04074
Odyssey Research
Scottsbluff, Nebraska, 69361
AMIT SHAH Medical Group
Sebring, Florida, 33872
LSU Health Sciences Center
Shreveport, Louisiana, 71103
Northern Indiana Oncology Associates
South Bend, Indiana, 46617
Highlands Oncology Group
Springdale, Arkansas, 72764
Springfield Clinic, LLP
Springfield, Illinois, 62703
Santee Hematology/Oncology
Sumter, South Carolina, 29150
SUNY Upstate Medical University
Syracuse, New York, 13210
Syracuse VA Medical Center
Syracuse, New York, 13210
Northern Hematology-Oncology
Thornton, Colorado, 80260
Mitchell Folbe, MD, PC
Troy, Michigan, 48085
Arizona Oncology Assoc.
Tucson, Arizona, 85715
Blood and Cancer Center of East Texas
Tyler, Texas, 75701
Tyler Hematology Oncology, PA
Tyler, Texas, 75701
Cancer Institute of New Jersey at Cooper University Hospital
Voorhees Township, New Jersey, 08043
Cedar Valley Medical Specialists
Waterloo, Iowa, 50702
Masoom Kandahari, MD
Woodbridge, Virginia, 22191
Forum Health Cancer CareCenter
Youngstown, Ohio, 44501
About this study
This study will evaluate the effects of an investigational drug in combination with chemotherapy in patients with stage IIIB/IV non-small cell lung cancer. This study will measure the effects of this combination on progression of lung cancer, cancer response to treatments, and development of cancer-related bone lesions.
- Conditions
- Non Small Cell Lung Carcinoma
- Being tested
- zoledronic acid, Taxotere, Carboplatin
- Keywords
- lung cancer, ZPACT, US75, Bone Metastases
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
zoledronic acidDrug
TaxotereDrug
CarboplatinDrug
| Study group | Role | What they receive |
|---|---|---|
| Zometa® | Experimental | 4mg monthly for 12 months from date of first chemotherapy dose Receives: Drug: zoledronic acid; Drug: Taxotere; Drug: Carboplatin |
| no further treatment | No intervention | Control arm; no further treatment. Follow-up monthly for 12 months from date of first chemotherapy dose |
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jul 2004 (estimated)
- Study startApr 2004
- Primary completionOct 2007
- Study completionOct 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Non Small Cell Lung CarcinomaStudies of the same condition, open and under way.
- More trials run by Novartis PharmaceuticalsThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 250 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Novartis Pharmaceuticals, Study director, Novartis Pharmaceuticals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00086268
- Sponsor's protocol ID
- CZOL446EUS75
- Other IDs
- US 75
- Acronym
- ZPACT
- Status last verified
- Sep 2017
- First submitted
- 29 Jun 2004
- Last updated
- 13 Sep 2017
- Results posted
- No
Publications
Pandya KJ, Gajra A, Warsi GM, Argonza-Aviles E, Ericson SG, Wozniak AJ. Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer. Lung Cancer. 2010 Mar;67(3):330-8. doi: 10.1016/j.lungcan.2009.04.020. Epub 2009 Jun 2.
PubMed 19493585
Study at a glance
From the registry record, last updated by the sponsor on 13 Sep 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Non-small Cell Lung Cancer Study US75 (Z-PACT)
- ClinicalTrials.gov ID
- NCT00086268
- Acronym / sponsor ID
- ZPACT / CZOL446EUS75
- Conditions
- Non Small Cell Lung Carcinoma
- Keywords
- lung cancer, ZPACT, US75, Bone Metastases
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 250 participants (actual)
- Lead sponsor
- Novartis PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- Apr 2004
- Primary completion
- Oct 2007 (actual)
- Study completion
- Oct 2007 (actual)
- First posted
- 1 Jul 2004 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will evaluate the effects of an investigational drug in combination with chemotherapy in patients with stage IIIB/IV non-small cell lung cancer. This study will measure the effects of this combination on progression of lung cancer, cancer response to treatments, and development of cancer-related bone lesions.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Zometa® | Experimental | Drug: zoledronic acid, Drug: Taxotere, Drug: Carboplatin4mg monthly for 12 months from date of first chemotherapy dose |
| no further treatment | No intervention | –Control arm; no further treatment. Follow-up monthly for 12 months from date of first chemotherapy dose |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Male or Female patients at least of 18 years old
- Patients with diagnosed non-small cell lung cancer that cannot be treated by surgery
- Women must not be pregnant or attempting to become pregnant
- Able and willing to sign informed consent
Key exclusion criteria (4 listed)
- Patients with cancer that has spread to the bone
- Patients with cancer that has spread to the brain who are receiving treatment
- Patients with kidney disease
- Patients treated with other investigational drugs
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| zoledronic acid | Drug | Zometa® |
| Taxotere | Drug | Zometa® |
| Carboplatin | Drug | Zometa® |
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Sep 2017.
- Results publication: PubMed 19493585Pandya KJ, Gajra A, Warsi GM, Argonza-Aviles E, Ericson SG, Wozniak AJ. Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer. Lung Cancer. 2010 Mar;67(3):330-8. doi: 10.1016/j.lungcan.2009.04.020. Epub 2009 Jun 2.
Related trials for Non Small Cell Lung Carcinoma
Active, not recruitingPhase 3
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
Non-small Cell Lung Cancer Stage IV
RecruitingPhase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Active, not recruitingPhase 3
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8
Active, not recruitingPhase 1
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
RecruitingPhase 3
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Lung Non-Small Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Novartis Pharmaceuticals study director
Novartis Pharmaceuticals
80 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing zoledronic acid, Taxotere and Carboplatin in people with Non Small Cell Lung Carcinoma, run by Novartis Pharmaceuticals at 80 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Sep 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 80 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00086268, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Sep 2017; AzTrials last refreshed its copy on 27 Oct 2026.